A Prospective Active-Reference Study of Gaboxadol in Primary Insomnia

Lundbeck

Status and phase: Completed; Phase 3

Conditions: Primary Insomnia

Treatments: Drug: Gaboxadol

Study type: Interventional

Funder types: Industry

Identifiers

NCT00209937

99775

Details and patient eligibility

About

To evaluate the efficacy safety and tolerability of gaboxadol in primary insomnia

Full description

To compare the hypnotic efficacy and safety of different dose levels of gaboxadol with placebo in non-elderly patients with primary insomnia over two weeks of treatment

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• diagnosis of Primary insomnia

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind